High Expression of UBE2C is Associated with the Aggressive Progression and Poor Outcome of Malignant Glioma

Overview

Journal Oncol Lett

Specialty Oncology

Date 2016 Mar 22

PMID 26998166

Citations 28

Authors

Ruimin Ma

Xixiong Kang

Guojun Zhang

Fang Fang

Yamei Du

Hong Lv

Affiliations

Soon will be listed here.

Abstract

Ubiquitin-conjugating enzyme E2C (UBE2C) is a key regulator of cell cycle progression and is involved in the tumorigenesis of a variety of cancers. Previous studies have demonstrated that UBE2C is an important factor in the malignant progression of astrocytic tumors. However, the association between UBE2C expression and clinical prognosis of glioma patients has not been defined. In the present study, the expression of UBE2C in gliomas and non-cancerous brain tissues were detected by microarray and immunohistochemical analysis. The association between UBE2C expression and clinicopathological characteristics of the glioma patients was evaluated. The Kaplan-Meier method and multivariate Cox's proportional hazards model were used to analyze the survival time of the patients. The results demonstrated that the expression levels of UBE2C in anaplastic gliomas and glioblastoma (GBM) patients were significantly higher compared to low-grade gliomas, in microarray and immunohistochemistry analysis. A higher UBE2C expression was associated with a significantly decreased overall survival time in patients possessing anaplastic gliomas (P<0.01) and GBMs (P<0.05). Multivariate analysis of 80 GBM patients revealed that UBE2C expression was an independent prognostic factor. To the best of our knowledge, the present data suggest for the first time that UBE2C overexpression is strongly associated with an aggressive progression and poor outcome of malignant glioma. Therefore, UBE2C overexpression may be used as a predictor of poor prognosis in patients with malignant glioma.

Citing Articles

A bird's eye view to the homeostatic, Alzheimer and Glioblastoma attractors.

Nieves J, Gil G, Gonzalez A Heliyon. 2025; 11(4):e42445.

PMID: 40028606 PMC: 11867265. DOI: 10.1016/j.heliyon.2025.e42445.

Ubiquitination-Binding Enzyme 2C is Associated with Cancer Development and Prognosis and is a Potential Therapeutic Target.

Zhao M, Li J, Wang R, Mi L, Gu Y, Chen R Onco Targets Ther. 2024; 17:1159-1171.

PMID: 39678016 PMC: 11637980. DOI: 10.2147/OTT.S485053.

Inferring Diagnostic and Prognostic Gene Expression Signatures Across WHO Glioma Classifications: A Network-Based Approach.

Coletti R, Leiria de Mendonca M, Vinga S, Lopes M Bioinform Biol Insights. 2024; 18:11779322241271535.

PMID: 39286768 PMC: 11403688. DOI: 10.1177/11779322241271535.

UBE2C enhances temozolomide resistance by regulating the expression of p53 to induce aerobic glycolysis in glioma.

Zhou K, Wang D, Du X, Feng X, Zhu X, Wang C Acta Biochim Biophys Sin (Shanghai). 2024; 56(6):916-926.

PMID: 38634120 PMC: 11214954. DOI: 10.3724/abbs.2024033.

Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent Glioblastoma.

Wang X, Ge Y, Hou Y, Wang X, Yan Z, Li Y Cancer Gene Ther. 2024; 31(5):790-801.

PMID: 38429367 DOI: 10.1038/s41417-024-00740-4.

References

Hershko A, Ciechanover A . The ubiquitin system. Annu Rev Biochem. 1998; 67:425-79. DOI: 10.1146/annurev.biochem.67.1.425. View

Bavi P, Uddin S, Ahmed M, Jehan Z, Bu R, Abubaker J . Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma. Am J Pathol. 2011; 178(5):2109-20. PMC: 3081207. DOI: 10.1016/j.ajpath.2011.01.034. View

Zhang W, Qiu X, Chen B, Li S, Cui Y, Ren H . Antiangiogenic therapy with bevacizumab in recurrent malignant gliomas: analysis of the response and core pathway aberrations. Chin Med J (Engl). 2009; 122(11):1250-4. View

Jiang L, Wang T, Bao Y, Qian J, Wu X, Hu G . A study of UbcH10 expression and its association with recurrence of meningiomas. J Surg Oncol. 2011; 106(3):327-31. DOI: 10.1002/jso.22141. View

Nitta M, Muragaki Y, Maruyama T, Iseki H, Ikuta S, Konishi Y . Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype. Neurol Med Chir (Tokyo). 2013; 53(7):447-54. DOI: 10.2176/nmc.53.447. View

Martinho O, Granja S, Jaraquemada T, Caeiro C, Miranda-Goncalves V, Honavar M . Downregulation of RKIP is associated with poor outcome and malignant progression in gliomas. PLoS One. 2012; 7(1):e30769. PMC: 3264629. DOI: 10.1371/journal.pone.0030769. View

Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K . Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007; 121(1):33-8. DOI: 10.1002/ijc.22605. View

Yamanaka A, Hatakeyama S, Kominami K, Kitagawa M, Matsumoto M, Nakayama K . Cell cycle-dependent expression of mammalian E2-C regulated by the anaphase-promoting complex/cyclosome. Mol Biol Cell. 2000; 11(8):2821-31. PMC: 14958. DOI: 10.1091/mbc.11.8.2821. View

Shen Z, Jiang X, Zeng C, Zheng S, Luo B, Zeng Y . High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer. 2013; 13:192. PMC: 3637393. DOI: 10.1186/1471-2407-13-192. View

10.

Townsley F, Aristarkhov A, Beck S, Hershko A, Ruderman J . Dominant-negative cyclin-selective ubiquitin carrier protein E2-C/UbcH10 blocks cells in metaphase. Proc Natl Acad Sci U S A. 1997; 94(6):2362-7. PMC: 20093. DOI: 10.1073/pnas.94.6.2362. View

11.

Li S, Song Y, Zhang H, Jin B, Liu Y, Liu W . UbcH10 overexpression increases carcinogenesis and blocks ALLN susceptibility in colorectal cancer. Sci Rep. 2014; 4:6910. PMC: 4223683. DOI: 10.1038/srep06910. View

12.

Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A . UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003; 63(14):4167-73. View

13.

Rape M, Kirschner M . Autonomous regulation of the anaphase-promoting complex couples mitosis to S-phase entry. Nature. 2004; 432(7017):588-95. DOI: 10.1038/nature03023. View

14.

Parris T, Danielsson A, Nemes S, Kovacs A, Delle U, Fallenius G . Clinical implications of gene dosage and gene expression patterns in diploid breast carcinoma. Clin Cancer Res. 2010; 16(15):3860-74. DOI: 10.1158/1078-0432.CCR-10-0889. View

15.

Rape M, Reddy S, Kirschner M . The processivity of multiubiquitination by the APC determines the order of substrate degradation. Cell. 2006; 124(1):89-103. DOI: 10.1016/j.cell.2005.10.032. View

16.

Fujita T, Ikeda H, Taira N, Hatoh S, Naito M, Doihara H . Overexpression of UbcH10 alternates the cell cycle profile and accelerate the tumor proliferation in colon cancer. BMC Cancer. 2009; 9:87. PMC: 2666760. DOI: 10.1186/1471-2407-9-87. View

17.

Wagner K, Sapinoso L, El-Rifai W, Frierson H, Butz N, Mestan J . Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin. Oncogene. 2004; 23(39):6621-9. DOI: 10.1038/sj.onc.1207861. View

18.

Joazeiro C, Weissman A . RING finger proteins: mediators of ubiquitin ligase activity. Cell. 2000; 102(5):549-52. DOI: 10.1016/s0092-8674(00)00077-5. View

19.

Berlingieri M, Pallante P, Guida M, Nappi C, Masciullo V, Scambia G . UbcH10 expression may be a useful tool in the prognosis of ovarian carcinomas. Oncogene. 2006; 26(14):2136-40. DOI: 10.1038/sj.onc.1210010. View

20.

Troncone G, Guerriero E, Pallante P, Pallante P, Berlingieri M, Ferraro A . UbcH10 expression in human lymphomas. Histopathology. 2009; 54(6):731-40. DOI: 10.1111/j.1365-2559.2009.03296.x. View